Invivyd, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. It developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. The company's pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrevimab, that is in phase 2/3 clinical trials for the prevention and treatment of COVID-19. It also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. The company has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

Period	Net Profit Margin
2021-12-31	N/A
2022-12-31	N/A
2023-12-31	N/A
2024-12-31	-669.42%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IVVD	$1.33	+3.49%	1.33M
3
4
5

Invivyd Inc. (IVVD) Profit Margin

Profit Margin Data

Get Invivyd Inc. Data in Excel

More IVVD Financial Data